fashion -WSS

fashion

author：leisure time 2025-08-11 11:45:57 - browse：365

Scientists Christina Frey and Paul Negulescu work in a lab at Vertex Pharmaceuticals. -- biotech coverage from STAT — Scientists Christina Frey and Paul Negulescu work in a lab at Vertex Pharmaceuticals in San Diego. Sandy Huffaker for STAT

A pain relief drug developed by Vertex Pharmaceuticals succeeded in late-stage clinical trials, the company announced Tuesday, bringing the biopharma giant a step closer to launching what observers believe could be a potential blockbuster and upending decades of pharma failure in a complicated field.

In a pair of randomized, placebo-controlled Phase 3 trials for patients with pain after a tummy tuck or bunion surgery, the drug showed statistically significant pain reduction compared to placebo, meeting the primary endpoints for these studies and the expectations of market analysts. But the experimental therapy didn’t relieve pain better than a combination of acetaminophen and the opioid hydrocodone, a key secondary endpoint observers had been waiting on. And in the bunionectomy trial, the opioid comparator outperformed VX-548 at soothing pain.

The drug, a small molecule known as VX-548, blocks pain-sensing neurons from signaling the pain without the addictive potential of opioids. It was generally safe, with fewer patients on VX-548 reporting adverse events than those taking the placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Explaining an after

knowledge

WSS

'Revelatory' study finds a smoking impact that remains after quitting

How digital tools helped lower hypertension in marginalized patients

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

Private equity deals in Medicare Advantage declines

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

A disappointing year of Humira biosimilars

entertainment

fashion

entertainment

Hepatitis C has a cure — but many Americans still lack access to it

Medicare must police algorithms in Medicare Advantage, Dems say

DIEP, the 'gold standard' of breast reconstruction, is under threat

What we’ve learned from the Aduhelm mess

23andMe had bad news about my health. I wish a person had delivered it

Sarepta Duchenne therapy fails to meet primary endpoint in trial

Trump demands the U.S. pay no more for drugs than other countries … again

Private equity deals in Medicare Advantage declines

Psychedelics group wrestles with new pharma identity

Key House Republican on health care plans exit from Congress

explore

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Humans aren't the only ones with an imagination. Rats have it too

Prime Medicine says its gene editing passes test in monkeys

Coloradans with cystic fibrosis could lose access to Trikafta

Infant mortality in U.S. rose last year for first time in decades: CDC

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

entertainment

knowledge

knowledge

explore